Compare Linde PLC (LIN) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Linde PLC trades at $495.32 (market cap $226.85B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Linde PLC is far larger — about 233.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Linde PLC pays a 1.3% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 89 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LIN | MRVI | |
|---|---|---|
Market Cap | $226.85B | $972.90M |
Volume | 1,386,042 | 4,325,710 |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $9.00 |
52-Week Low | $389.38 | $2.83 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $249.97B | $1.08B |
Dividend Yield | 1.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $492.11, up 0.98% today, near its 52-week high. The stock shows a bullish technical trend with strong fundamentals, including a 20.43% net income margin and consistent earnings beats. Recent news highlights its role in AI chip supply chains, while analyst consensus remains strongly positive with a $558.91 price target.
Outlook is favorable given robust profitability and growth in electronics end-markets, but risks include elevated valuation multiples and rising debt levels. The stock offers upside potential aligned with Wall Street optimism, though investors should weigh margin pressures and capital expenditure trends.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
